Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients

dc.authoridgurbuz, venhar/0000-0002-9777-5173
dc.authorwosidgurbuz, venhar/ABA-9285-2021
dc.contributor.authorGurbuz, Venhar
dc.contributor.authorKiliccioglu, Ilker
dc.contributor.authorDikmen, Asiye Ugras
dc.contributor.authorBilen, Cenk Y.
dc.contributor.authorSozen, Sinan
dc.contributor.authorKonac, Ece
dc.date.accessioned2021-12-01T18:49:19Z
dc.date.available2021-12-01T18:49:19Z
dc.date.issued2020
dc.department[Belirlenecek]en_US
dc.description.abstractAbnormal expression of enzymes involved in epigenetic mechanisms, such as DNA methyl transferases, can trigger large chaos in cellular gene expression networks and eventually lead to cancer progression. In our study, which is a pioneer in the literature that clinicopathologically evaluates the expression of 30 epi-miRNAs in prostate cancer (PCa), we investigated which of the new miRNA class epi-miRNAs could be an effective biomarker in the diagnosis and progression of PCa. In this study, the expression levels of 30 epi-miRNAs in whole blood samples from 25 control, 25 PCa and 40 metastatic PCa patients were investigated by the Quantitative Real-Time PCR method. Then, promoter methylation levels of 11 epi-miRNAs, whose expression levels were found to be significantly higher, were examined by methylation-specific qPCR method. The correlations between miRNA expression levels and clinicopathological parameters (Gleason Score (GS), PSA levels, TNM Staging) in different stages of PCa groups as well as disease-specific expression levels were examined. We found a hypomethylation in the promoter regions of miRNAs that showed a direct proportional increase with PSA levels (miR34b/c, miR-148a, miR-152), GS's (miR-34a-5p, miR-34b/c, miR-101-2, miR-126, miR-148a, miR-152, miR-1855p) and T staging (miR-34a-5p, miR-34b/c, miR-101-2, miR-126, miR-140, miR-148a, miR-152, miR-185-5p) (p < 0.05). When miR-200a/b was evaluated according to clinicopathological parameters, it acted as an oncomiR in local/local advanced PCa and as a tumor-suppressor-miR in metastatic stage. This study is novel in the sense that our findings draw attention to the important role of miRNAs as diagnostic and prognostic biomarkers in PCa.en_US
dc.description.sponsorshipGazi University Research FundGazi University [01/2019-11]en_US
dc.description.sponsorshipThis study was conducted with financial support from the Gazi University Research Fund [the project code number 01/2019-11].en_US
dc.identifier.doi10.1016/j.gene.2020.144963
dc.identifier.issn0378-1119
dc.identifier.issn1879-0038
dc.identifier.scopus2-s2.0-85088216243en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.gene.2020.144963
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10702
dc.identifier.volume758en_US
dc.identifier.wosWOS:000564694000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofGeneen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiomarkersen_US
dc.subjectDNA methylationen_US
dc.subjectEpi-microRNAsen_US
dc.subjectPrognosisen_US
dc.subjectProstate canceren_US
dc.subjectDocetaxel Resistanceen_US
dc.subjectTumor-Suppressoren_US
dc.subjectLung-Canceren_US
dc.subjectMicrornaen_US
dc.subjectBiomarkersen_US
dc.subjectMethylationen_US
dc.subjectMir-148Aen_US
dc.subjectIdentificationen_US
dc.subjectProliferationen_US
dc.subjectEpigeneticsen_US
dc.titleComparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
10702.pdf
Boyut:
371.71 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text